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Mycobacterium triplex, a recently described, potential-
ly pathogenic species, caused disease primarily in
immunocompromised patients. We report a case of pul-
monary infection due to this mycobacterium in an immuno-
competent patient and review the characteristics of two
other cases. In our experience, Mycobacterium triplex pul-
monary infection is unresponsive to antimycobacterial
chemotherapy.
N
ontuberculous mycobacteria (NTM) are ubiquitous
organisms, commonly isolated from environmental
and animal sources (1), whose pathogenicity may vary
according to the host’s immune status. Although exposure
to NTM frequently causes no symptoms, clinical manifes-
tations may range from hypersensitivity reactions (2) to
destructive, even fatal, lung disease. In the case of lung
disease caused by NTM, clinical and radiologic features
are sometimes indistinguishable from those seen in lung
disease caused by Mycobacterium tuberculosis complex
(MTB). The clinical importance of NTM is often difficult
to determine, especially in patients with chronic, preexist-
ing lung disease; criteria for diagnosing disease caused by
NTM, most recently updated by the American Thoracic
Society in 1997 (3), need to be properly fulfilled.
M. triplex was first described in 1996 (4). Investigators
reported a group of slowly growing, nonpigmented
mycobacteria, resembling M. simiae or M. avium complex
(MAC) in biochemical tests, which did not react with the
commercial probe designed for MAC. The primary charac-
terization of this new organism relied on conventional bio-
chemical tests and analysis of mycolic acids with
high-performance liquid chromatography (HPLC), but
conclusive evidence was based on sequencing the 16S
rRNA hypervariable region. In HPLC analysis, M. triplex
produces a triple-clustered mycolic acid profile closely
related to those of M. simiae,  M. genavense, and the
recently described M. sherrisii (5), but practically indistin-
guishable from that of M. lentiflavum, a novel mycobac-
terium characterized by Springer et al. (6). Phylogenetic
studies showed that M. triplex and  M. lentiflavum are
closely related to M. simiae and M. genavense.
M. triplex has been reported to cause episodic infection
in AIDS patients or in those with other immunocompro-
mising diseases (7–9). We present the case of an apparent-
ly immunocompetent patient with pulmonary disease
caused by this mycobacterium and review the characteris-
tics of two similar cases.
The Case
On January 2002, a 54-year-old, HIV-negative, white
woman was referred to the outpatient pulmonary service
because of persistent cough lasting >2 years and fatigue.
She lived in an urban area, had smoked cigarettes (40
packs/year) for several years, but did not report any histo-
ry of alcoholism or use of immunosuppressive drugs.
Results of physical examination and routine laboratory
tests, including a standard tuberculin skin test, were unre-
markable. A chest x-ray showed considerable fibrotic
interstitial changes associated with patchy parenchymal
shadowing in both lower fields and multiple thin-walled
cavitary lesions (0.7–3.5 cm) in both upper lobes. A com-
puted tomographic (CT) scan of the chest confirmed the
above lesions, including multifocal bronchiectases in the
right middle lobe and multiple small nodules in the lower
lobes. Smears for acid-fast bacilli (AFB) were positive on
two bronchial washing samples. These specimens pro-
duced negative results when tested by a commercial strand
displacement amplification assay (Becton Dickinson
Biosciences, Sparks, MD) specific for MTB.
Chemotherapy with isoniazid, rifampin, and ethambutol
was started. Cultures produced a slow-growing, nonpig-
mented mycobacterium that was identified in June 2002 as
M. lentiflavum, according to the HPLC pattern of mycolic
acids. One more bronchial specimen collected in mid-June
was AFB smear-positive and yielded the same organism as
was detected in January. Isolates were considered clinical-
ly relevant, and chemotherapy was changed to ethambutol
and clarithromycin. 
In December 2002, after 6 months of treatment, a CT
scan did not show reduction of pulmonary lesions,
although the general condition of the patient had slightly
improved. Smears from one out of four additional
bronchial washing samples were positive for AFB, and all
specimens yielded the same mycobacterium previously
detected. A more accurate evaluation of clinical isolates
showed that their phenotypic pattern was different from
that of M. lentiflavum by results of some biochemical tests
and the absence of pigmentation. Further gene sequencing
study of the 16S rDNA showed that our isolates exhibited
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(ATCC 70071). In March 2003, although chemotherapy
was well tolerated, microbiologic tests of two bron-
choalveolar lavage (BAL) specimens continued to be AFB
smear- and culture-positive. Consequently, chemotherapy
was changed to include levofloxacin, ethambutol, and clar-
ithromycin. In October 2003, chest x-ray examination and
a CTscan showed a slight reduction in the size of lung cav-
ities. The patient continues to receive medication, and the
radiologic picture has not improved.
Microbiologic Aspects
After standard N-acetyl-L-cysteine-sodium hydroxide
decontamination (10), bronchoaspirate washing and BAL
specimens were stained with routine Ziehl-Neelsen and
cultured by a combination of the radiometric Bactec sys-
tem (Becton Dickinson Biosciences) and Löwenstein-
Jensen medium. Recovered strains were tested with a
commercial multiplex line probe assay (Inno-LiPA
Mycobacteria v2, Innogenetics, Ghent, Belgium) specific
for MAC and 16 other different mycobacterial species
(11). Further identification studies were performed by
mycolic acid HPLC analysis (12) and 16S rDNA sequenc-
ing (13). Drug susceptibility pattern was determined in liq-
uid medium by using the radiometric macrodilution
method developed for MAC (14). 
M. triplex strains were repeatedly isolated on both liq-
uid and solid media (Table 1). An extended panel of bio-
chemical and cultural tests was used for conventional
identification (10) (Table 2). The hybridization test per-
formed with the multiplex line probe assay was negative
apart from the genus-specific line probe. Final identifica-
tion was achieved by 16S rDNA gene sequencing. In fact,
while HPLC profile was poorly discriminative between
M. lentiflavum and  M. triplex (Figure 1), 16S rDNA
sequencing showed 100% homology with the M. triplex
reference strain, which allowed the attribution of all our
strains to this species (Figure 2). MICs (µg/mL) performed
on the first isolate were the following: streptomycin 6.0,
isoniazid  >0.5, rifampin >2.0, ethambutol 7.5,
ciprofloxacin 4.0, clarithromycin 8.0, amikacin 8.0,
ethionamide 2.5, and rifabutin 0.5. Drug susceptibility
testing was completed after 6 days. Tentative interpreta-
tions of MIC results, according to NCCLS M24-A(17) and
data from Heifets (18), are reported in Table 1.
Conclusions 
A search of the literature from 1996 (when M. triplex
was first described) to January 2004 yielded two reports of
pulmonary infections in immunocompetent patients
(15,16). In those reports, clinical and radiographic features
of M. triplex pulmonary infection did not differ substan-
tially from those of TB and other NTM. Cough, hemopty-
sis, and fatigue were the primary symptoms, while
radiographic studies found pulmonary nodules most com-
monly, followed by lung infiltrates, multifocal bronchiec-
tasis, and cavitations (Table 1). No patient had underlying
diseases when pulmonary infection with M. triplex was
diagnosed, and tuberculin skin test results were negative or
not reported. Although a history of preexisting pulmonary
lesions could not be documented for these patients, repeat-
ed isolation of mycobacteria from different respiratory
samples and the absence of other possible causes of pul-
monary disease suggest that M. triplex was likely to cause
symptomatic infection rather than colonization (3).
M. triplex strains were isolated on both liquid and solid
media in our case, while culture media were not reported
in the other two previously published cases. One case
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tests for conventional identification that showed the
absence of pigment and positive reactions to nitrate reduc-
tase, urease, and semiquantitative catalase as the most use-
ful characteristics for tentative identification (15). All
strains failed to hybridize with the commercially available
genetic probe for MAC (Accuprobe, Gen-Probe Inc., San
Diego, CA), so all reported cases could be definitively
identified by 16S rRNA gene sequencing and similarity
search with the BLAST alignment software
(www.blast.genome.ad.jp). One strain showed 100%
homology with the reference strain, while another showed
homology of 99.5% and, therefore, despite its close rela-
tionship, was regarded as a variant of M. triplex (15).
Patients (including our case-patient) were given differ-
ent treatment regimens with two to four antimicrobial
agents. Ethambutol, rifampin, clarithromycin, and
ciprofloxacin were mainly used (Table 1). Clinical
improvement, as defined by resolution of symptoms and
radiographic findings (infiltrates and cavitary lesions), was
obtained within 10 months after therapy was initiated in
one of three patients. One patient improved when clar-
ithromycin and ciprofloxacin were added to the regimen,
while another was reported to have improved after drug
therapy was initiated (16). Our patient was still sputum
smear and culture–positive 2 years after therapy was initi-
ated, despite exhibiting minor evidence of clinical and
radiologic improvement. 
Our findings show that M. triplex infrequently causes
pulmonary disease in immunocompetent persons.
Treatment with a three- or four-drug combination, includ-
ing clarithromycin, ciprofloxacin, and ethambutol, was
shown to be associated with reduced symptoms and good
clinical outcome. Although at present only 16S rDNA
sequencing can identify M. triplex, presumptive identifica-
tion can be made when a slow-growing, nonpigmented
NTM reduces nitrates, produces urease and semiquantita-
tive catalase, and exhibits a three-clustered HPLC profile. 
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Figure 1. Comparison of high-performance liquid chromatography
phenotypes of A) Mycobacterium triplex, B) M. lentiflavum, and
C) M. simiae. IS; internal standard.DISPATCHES
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Figure 2. Sequence alignment of
the hypervariable region A within
the 16s RNA gene of the studied
isolate and related species.
Mycobacterium tuberculosis was
used as the reference sequence.
Nucleotides different from those
of M. tuberculosis are indicated;
dots indicate identity.